Sagimet Biosciences to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ
Rhea-AI Summary
Sagimet Biosciences (Nasdaq: SGMT) announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on May 19, 2026, in New York.
A fireside chat at 2:00 p.m. ET will be webcast live and archived for 90 days on Sagimet’s website.
Positive
- None.
Negative
- None.
News Market Reaction – SGMT
In the May 13 session, SGMT declined 0.65%, reflecting a mild negative market reaction. Our momentum scanner triggered 2 alerts that day, indicating moderate trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Earnings and updates | Positive | -0.5% | Q1 2026 results, $175M financing, extended acne cash runway and lower net loss. |
| May 11 | Clinical data preview | Positive | -0.3% | Preclinical mechanism-of-action data for FASN inhibitors supporting planned Phase 3 acne trial. |
| Apr 27 | Equity offering | Positive | +38.6% | Pricing of $175M Series A stock offering at $6.00 per share for acne programs. |
| Apr 27 | Strategic update | Positive | +38.6% | Dermatology-focused strategy, planned US Phase 3 acne trial and positive China Phase 3 safety. |
| Apr 20 | Management change | Neutral | -0.5% | Appointment of new Chief Medical Officer and inducement stock option grant. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news often skewed positive (financing, pipeline progress), yet follow-up earnings and data updates saw slight negative reactions while the April 27 strategic update and offering coincided with a sharp upside move.
Over the last month, Sagimet issued multiple updates. On April 27, 2026, strategic and corporate updates plus the pricing of a $175.0M offering in Series A stock both coincided with a strong 38.57% gain. A management change on April 20 saw only a small decline. More recently, positive acne mechanism-of-action data and Q1 2026 results with reduced R&D and narrower net loss were followed by modest negative moves, framing today’s conference appearance as part of an ongoing investor communication effort.
AI-generated analysis. How Rhea-AI works. Not financial advice.
SAN MATEO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced that management will participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026, in New York, NY with a fireside chat at 2pm ET (link here).
A webcast of the fireside chat will be available in the Investors & Media section of Sagimet’s website at www.sagimet.com, with an archived replay available for 90 days following the live event.
About Sagimet Biosciences
Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types. For additional information about Sagimet, please visit www.sagimet.com.
Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com
Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com
